FDA Pre-Approval Inspections (PAI) Guide for Non-ICH Facilities

The FDA conducted 1,927 facility inspections in 2024 and issued warning letters following 42% of them. But the pattern that regulatory and compliance professionals consistently observe is specific: non-ICH country facilities, particularly those in India and China, account for a disproportionate share of serious inspection outcomes. Data integrity violations, process validation gaps, laboratory control deficiencies, and inadequate deviation management are the four citation clusters that appear across FDA Form 483 observations and warning letters issued to these sites with remarkable regularity.

A Pre-Approval Inspection (PAI) is triggered when a manufacturing site is named in a New Drug Application, Abbreviated NDA, or Biologics License Application, particularly when the site is named for the first time or has not been recently inspected. A PAI is not a routine GMP check. It is a targeted assessment of whether the facility can manufacture the specific product described in the application, at commercial scale, consistently, and in compliance with the methods and controls that were submitted. The distinction is critical because PAIs fail for reasons that routine inspections often miss.

What a FDA Pre-Approval Inspection Actually Evaluates

A PAI evaluates four primary areas. First, whether the manufacturing process described in the application can actually be executed at the facility as written. Second, whether the analytical methods in the CMC section have been validated and are actively in use at the site. Third, whether batch records and process data from exhibit batches are accurate, complete, and traceable. Fourth, whether the quality system can identify, investigate, and resolve deviations before they reach the finished product.

Inspectors verify data authenticity by comparing the CMC section against actual batch records from exhibit or process performance qualification batches. They audit laboratory systems for data integrity. They review equipment qualification status. They assess whether critical process parameters are controlled as described. A facility that runs processes differently from how they are described in the application will receive a Complete Response Letter, regardless of its general GMP standing.

Deficiency Pattern 1: Data Integrity Failures

Data integrity violations are the single most frequently cited issue in FDA inspections of non-ICH facilities in 2024 and 2025. Specific patterns include missing audit trails in chromatography data systems, backdated entries in electronic records, deletion or overwriting of out-of-specification laboratory results without documented investigation, and parallel paper records that do not match electronic data.

In March 2025, the FDA issued a Complete Response Letter for the camrelizumab/rivoceranib NDA, citing unresolved manufacturing deficiencies at Jiangsu Hengrui Pharmaceuticals’ Suzhou facility. The facility had received a Form 483 in 2024 that documented data integrity failures, contamination risks, and raw material handling issues. In early 2025, the FDA issued a warning letter to Tyche Industries for falsification of manufacturing data, inadequate cleaning procedures, and failure to test incoming raw materials, resulting in Import Alert 66-40 barring importation into the US.

The FDA’s requirements under 21 CFR Part 11 mandate that electronic records be accurate, complete, attributable, legible, and contemporaneous. Facilities that allow analysts to delete and rerun tests without full documentation, or that maintain hybrid paper-electronic systems without SOPs for record reconciliation, are structurally exposed at every inspection.

Deficiency Pattern 2: Process Validation Gaps

Non-ICH facilities frequently submit applications describing processes from small-scale development batches, then attempt to exhibit batches at commercial scale without adequate process characterization. The FDA expects the submitted process to reflect a well-understood design space with defined critical process parameters (CPPs) and critical quality attributes (CQAs), supported by process performance qualification (PPQ) data from commercial-scale equipment.

Facilities that cannot demonstrate that commercial-scale PPQ batches were manufactured using the same equipment and operating within the same parameter ranges described in the application will receive observations. For sterile manufacturing, the FDA has adopted the key tenets of EU GMP Annex 1, requiring a documented contamination control strategy (CCS), environmental monitoring programs, aseptic process simulations, and personnel qualification records.

Deficiency Pattern 3: Laboratory Control System Deficiencies

The laboratory receives the same scrutiny as the manufacturing floor during a PAI. Common citations involve analytical methods described as validated in the submission but without validation reports at the site, expired or improperly qualified reference standards, stability chambers without continuous calibration and monitoring records, and out-of-specification investigation procedures that are inadequately defined or inconsistently applied.

A recurring pattern in non-ICH facilities is the submission of stability data generated at a development laboratory, with commercial release testing intended at a different site. When the PAI covers the intended commercial testing laboratory, and that site has not yet implemented the validated methods or established the reference standard program, the inspection results in a major deficiency.

Deficiency Pattern 4: Deviation and CAPA System Failures

FDA’s current inspection posture places heavy emphasis on CAPA effectiveness. Investigators are not simply confirming whether a CAPA was opened. They are evaluating whether the root cause analysis was genuinely analytical, whether implemented corrections addressed the root cause, and whether effectiveness checks confirm the CAPA worked. CAPA deficiencies are consistently the tipping point for escalation from Form 483 observations to warning letters.

At non-ICH facilities, the deviation management system is often the weakest link. Deviations are closed without root cause identification, classified as minor when data suggests a major impact, or investigated by the personnel who executed the deviation. Where a product is released before deviations are fully investigated and dispositioned, the quality system has failed its core function.

Inspection Resources and Oversight Gaps

A 2025 Government Accountability Office report confirmed that the FDA has 51 investigator vacancies, many critical to foreign inspections. A congressional analysis found stark variations among investigators, with some finding compliance issues at nearly every site they visited while others rarely cited violations at facilities in countries with known quality control failures. The FDA has launched a pilot program for unannounced foreign inspections in response.

This context does not excuse non-compliance. It signals that facilities that have not been recently inspected may have accumulated systemic deficiencies that a PAI will expose completely. The risk-based inspection scheduling that the FDA applies means that a PAI may be a facility’s first substantive FDA inspection in several years.

What Non-ICH Facilities Must Do Differently Before a PAI

Commission a PAI-readiness assessment from a consultant with direct recent FDA inspection experience at similar product types. Internal audits alone miss the behavioral and systemic patterns that external assessors identify.
Map every assertion in the CMC section to physical evidence at the manufacturing site. Method validations, PPQ protocols, equipment qualification, and reference standard programs must all exist at the site before the inspection.
Implement a fully validated electronic laboratory data management system with complete, unmodifiable audit trail capability. Hybrid paper-electronic records are among the first things PAI inspectors examine.
Conduct a tabletop exercise against recent FDA warning letters issued to Indian and Chinese facilities. Many deficiency patterns recur. Checking against known failure modes is a direct and efficient preparation.
Establish a front room and back-room protocol for managing the inspection. The front room is where the FDA investigator works. The back room is where your team retrieves documents, tracks questions, and manages technical responses. This protocol reduces error rates and response delays under inspection conditions.

Conclusion

A PAI failure is not a simple delay. It places the entire application at risk of a Complete Response Letter requiring additional batches, new studies, or system remediation before resubmission. Given the commercial stakes of a new drug approval, particularly in competitive therapeutic categories, thorough PAI preparation is one of the highest-value activities a regulatory and quality team can undertake.